Abbreviations & Acronyms AIPC = androgenindependent prostate cancer AR = androgen receptor AR-V7 = androgen receptor splice variant 7 BSC = best supportive care BSI = Bone Scan Index CAB = combined androgen blockade CRPC = castration-resistant prostate cancer HHSPC = hormonehypersensitive prostate cancer PFS = progression-free survival PSA = prostate-specific antigen Ra-223 = radium-223 Abstract: When advanced prostate cancer recurred during hormonal therapy and became the castration-resistant prostate cancer, "vintage hormonal therapy," such as antiandrogen alternating therapy or estrogen-related hormonal therapy, was widely carried out in Japan until 2013. This vintage hormonal therapy controlled the progression of castration-resistant prostate cancer. When castration-resistant prostate cancer relapses during these therapies, chemotherapy using docetaxel has been carried out subsequently. Since new hormonal therapies using abiraterone acetate and enzalutamide, which improve the prognosis of castration-resistant prostate cancer, became available in Japan from 2014, therapeutic options for castration-resistant prostate cancer have increased. Furthermore, the improvement of the further prognosis is promising by using cabazitaxel for docetaxel-resistant castration-resistant prostate cancer and radium-223 for castration-resistant prostate cancer with bone metastasis. An increase in therapeutic options gives rise to many questions, including best timing to use them and the indication. Furthermore, physicians have to consider the treatment for the recurrence after having carried out chemotherapy. We want to argue the difference in hormonal therapy between Japan and Western countries, and problems when carrying out new treatments, and the importance of imaging in the present review article.
Introduction
The initial treatment for advanced prostate cancer is mainly hormonal therapy. However, the treatment strategy is different between Japan and Western countries. Many physicians in Western countries do not recommend CAB; that is, the combined use of castration and an antiandrogen. 1 Although the addition of antiandrogen to castration for advanced prostate cancer might produce improvement of approximately 2% or 3% in overall survival, it does not produce great benefit for patients. 2 This could be one of the reasons why they prefer castration only. In contrast, advanced prostate cancer is treated with CAB at many institutions in Japan. At least until the first half of 2014, various forms of hormonal therapy (so-called vintage hormonal therapy) have been carried out for patients with prostate cancer that is advanced to CRPC. [3] [4] [5] Dexamethasone also has favorable effects on CRPC. 6 Chemotherapy using docetaxel has become available for recurrence after these vintage hormonal therapies in Japan since 2008. 7 BSC is chosen once the efficacy of docetaxel is lost. Since 2014, novel drugs for hormonal therapy (enzalutamide and abiraterone) and chemotherapy (cabazitaxel) have been added to the coverage of the national health insurance system in Japan, and therapeutic approaches to CRPC have changed. Radium-223, a therapeutic agent for bone metastases of CRPC, was also made available for clinical use in 2016.
It is sometimes difficult to choose vintage hormonal therapy and new drugs for CRPC. We discuss the difference in management of hormonal therapies between Japan and Western countries, and how to use new drugs in the present review article.
Vintage hormonal therapy
The usefulness of CAB for advanced prostate cancer has been shown for stage C and D1 patients in a prospective clinical study carried out in Japan, excluding D2 patients. 8 In reality, however, there are many institutions in Japan that use CAB. CAB has also been proven to be useful for stage D2 patients through an analysis using the J-CaP database, although it was a retrospective study. 9 A possible reason why CAB is not very useful in Western countries is that a lower bicalutamide dose of 50 mg/day is used in Western countries, whereas the dose in Japan is 80 mg/day. It was clear that the higher dose of bicalutamide (100 mg/day or 150 mg/day) was more effective. 10 Therefore, it is potentially insufficient for 50 mg/day bicalutamide to exert the adequate antiandrogen effect. For CRPC occurring after CAB, it was common in Japan to confirm the antiandrogen withdrawal effect 11 or carry out alternative antiandrogen therapy. 3 In particular, it has been shown that alternative antiandrogen therapy decreased PSA in 60-80% of patients, and that decreased PSA was associated with good prognosis. 3, 12 After these reports on the usefulness of alternative antiandrogen therapy, this therapy has been commonly used in Japan. In addition, estrogen-related drugs, such as estramustine phosphate and ethinyl-estradiol, have also been used for post-recurrence of alternative antiandrogen therapy. In particular, the usefulness of ethinyl-estradiol has been assessed in retrospective studies, and favorable results have been obtained, showing PSA PFS of 10 months in CRPC patients in Japan, and PFS of 15.1 months in metastatic CRPC in Western countries. 4, 13 Administration of low-dose estramustine phosphate for CRPC showed a favorable response before docetaxel treatment (7.1-month median PFS, and 42-month overall survival in 31 patients with CPRC). 5 Also for dexamethasone, which has been used extensively for CRPC in Japan because of the benefit in treatment of CRPC, 14 the usefulness has been reconfirmed by a prospective study in Western countries comparing dexamethasone and prednisone for treatment of CRPC, in which PFS periods were 9.7 and 5.1 months, respectively. 15 In Western countries, prospective clinical studies of hormonal therapy combined with docetaxel from the initial treatment for advanced prostate cancer (CHAARTED study and STAMPEDE study), compared with 44 and 45 months in hormonal therapy alone groups, overall survival rates in docetaxel-hormonal therapy combination groups were 57.6 and 60 months, respectively. 16, 17 Meanwhile, a retrospective study using the large J-CaP database (n = 5618) has reported overall survival rates of 80.4, 67.2, and 45.6 months for stages M1a (n = 224), M1b (n = 4386) and M1c (n = 278), respectively, while showing good survival even without docetaxel in the initial treatment. 9 Although there could also be racial differences in responsiveness to hormonal therapy, good survival rates in Japan might be attributable in part to traditional treatments (vintage hormonal therapy) for CRPC including alternative antiandrogen therapy. 18 
New hormonal therapy
Enzalutamide, a second-generation antiandrogen, and abiraterone acetate, an adrenal androgen synthesis inhibitor, were added to the coverage of the national health insurance system in Japan in 2014, and have been available for unrestricted clinical use for treatment of CRPC. These two drugs have been shown to be useful for treatment of CRPC, whether or not docetaxel is used, in clinical studies carried out in Japan and in Western countries. [19] [20] [21] [22] [23] [24] [25] The present article briefly reviews the pathogenesis of CRPC and the mechanism of action of these two drugs against CRPC. 26 Prostate cancer becomes CRPC mainly through two mechanisms. One is adaptation, in which prostate cancer cells gradually adapt to a post-castration lowandrogen environment through reactivation of AR (hypersensitive AR). The other is clonal selection, in which AIPC cells, which exist more or less originally, increase after castration. The prognosis of CRPC is considered to differ depending on which of the two mechanisms has played a major role in CRPC development. In the case of Japan, given the aforementioned fact that certain therapeutic effects are produced by switching among antiandrogen agents, CRPC presumably develops mainly though adaptation according to the result of alternative antiandrogen therapy. 3 More specifically, in a majority of prostate cancer cases that have advanced to CRPC, testosterone and dihydrotestosterone are considered to be synthesized from androgen of adrenal origin in a microenvironment in prostate cancer tissues and stimulate reactivated hypersensitive AR. 27 If hypersensitive AR can be inhibited more strongly, CRPC caused through adaptation is likely to be more effectively treatable. This is realized by the advent of the two new drugs for hormonal therapy. Enzalutamide shows an approximately eightfold higher AR affinity than the first-generation antiandrogen, bicalutamide. 28 Furthermore, enzalutamide inhibits nuclear translocation of AR, and also inhibits AR from binding to DNA by preventing the cofactor from binding to AR. 28 Abiraterone, in contrast, inhibits androgen (dehydroepiandrosterone) synthesis in the testis, adrenal gland and prostate cancer tissues, decreases intracellular androgen levels, and inhibits AR activation. It is easy to understand if it is put this way: enzalutamide inhibits the downstream of AR more strongly, whereas abiraterone potently inhibits the upstream of AR. Nevertheless, enzalutamide and abiraterone might be equally effective in the sense that they basically inhibit the AR axis signaling pathway more strongly than conventional antiandrogens.
Indication of new hormonal therapies
In view of the pathogenesis of CRPC and the mechanism of action of the novel hormonal therapy drugs, it might be effective to start using these drugs as soon as the disease becomes CRPC. However, approximately 60% of patients are expected to enjoy improvements in prognosis by reducing PSA with vintage hormonal therapy as the initial treatment against CRPC, such as alternative antiandrogen therapy. 3 In addition, when patient background was compared between Western countries and Japanese clinical studies using post-docetaxel abiraterone and enzalutamide, vintage hormonal therapy was noticeably more commonly used among patients enrolled in studies in Japan (Fig. 1 ). 29 The results from studies carried out in Japan showed the effectiveness of these drugs, although the efficacy of new hormone therapy agents was somewhat lower than that in Western countries studies. 23, 24 Western countries studies also suggested that the efficacy of abiraterone does not change appreciably depending on whether diethylstilboestrol is used. 30 Thus, if new drugs can be expected to be effective even after treatment with vintage hormonal therapy, is it necessary to use new drugs in a hurry? Rather, the final prognosis after CRPC might be improved by using new drugs after using vintage hormonal therapy. Conversely, if response and survival benefit can be expected from the use of vintage hormonal therapy, such as alternative antiandrogen therapy, after using potent new hormone therapy drugs, it might be also valid; however, unfortunately, this remains to be tested in clinical studies. It would be acceptable to use vintage hormonal therapy for 1-3 months, and then decide whether to continue it or switch to some other treatment based on the change of PSA, radiographic change and symptoms.
Furthermore, there are some points to be aware of if new hormonal therapy drugs are to be used early in CRPC. There is a problem of drug resistance occurring as a result of long-term use. One of the mechanisms for abiraterone/enzalutamide resistance is expression of AR-V7. 31, 32 Studies in cultured cell systems have shown induction of AR-V7 expression as a result of increased RNA editing factors (U1A, U2A) after complete removal of androgen or the addition of enzalutamide, suggesting the possibility that long-term strong inhibition of AR activation leads to increased expression of AR-V7 and affects prognosis. 33 Enzalutamide/abiraterone converted AR-V7 to positive in patients whose AR-V7 was initially undetectable. 34 Furthermore, nuclear AR-V7 expression increased after enzalutamide/abiraterone in CRPC biopsy samples. 35 Among metastatic CRPC patients who received abiraterone or enzalutamide, overall survival and PSA-PFS in those positive for AR-V7 expression after the treatment have been reported to be significantly lower than in those with no expression. 34 If these drugs are to be started at an early stage of CRPC, physicians should be aware of the possibility of AR-V7 induction, although the emergence of AR-V7 might be involved in other mechanisms.
Chemotherapy
Since the effectiveness of docetaxel against CRPC was shown, 36, 37 docetaxel became available for medical care under the national insurance system in Japan in 2008. 7 Although the maximum use of docetaxel is limited to 10 courses in Western countries, there are no restrictions on this respect in Japan, and >10 courses of docetaxel can be used for some patients. 38 This could contribute to prolonging the prognosis for Japanese patients. However, long-term use of docetaxel in the standard regimen is not possible for many patients because of adverse effects, and biweekly administration of docetaxel has been reported to be effective and safe. 39 With this method, quality of life during treatment with docetaxel is expected to be improved without losing the effectiveness of docetaxel.
However, treatment becomes difficult once docetaxel resistance develops. One of the mechanisms for resistance to docetaxel is increased expression of P-glycoprotein from multiple drug-resistant gene 1.
40 P-glycoprotein is a cell membrane protein, and has a function of extracellularly releasing docetaxel that has entered cells. Cabazitaxel is an anticancer agent effective against docetaxel-resistant prostate cancer. 41 As cabazitaxel has a low affinity to P-glycoprotein, it is not captured by P-glycoprotein even when its expression is enhanced by docetaxel, and thus is not easily released outside of cancer cells. The effectiveness of cabazitaxel against docetaxel-resistant prostate cancer has also been shown in Japan. As cabazitaxel has a low affinity to P-glycoprotein, which is considered responsible for the blood-brain barrier, cabazitaxel is expected to be effective against brain metastases. 42, 43 However, it remains controversial as to when is the best time to switch docetaxel to cabazitaxel. In other words, it is difficult to judge how long to continue docetaxel, and when to switch to cabazitaxel while docetaxel is still effective.
Recently reported results from the CHAARTED and STAMPEDE trials have shown that overall survival was improved by using six courses of docetaxel from the initial androgen-deprivation therapy in prostate cancer patients with metastases. 16, 17 This hormonal chemotherapy from the initial treatment is now being established as a standard treatment in Western countries. Yet this treatment cannot be currently carried out in Japan because of insurance restrictions. This treatment might become available for patients in Japan someday, but then the patient selection would be a problem. The present authors formulated a hypothesis about why this treatment is effective for advanced prostate cancer. 29 This hormonal chemotherapy is thought to be useful for patients with highlevel AIPC before treatment with low-AR expression. AIPC is speculated to be more aggressive in patients with a very high grade of malignancy. 44, 45 AR immunostaining with a pattern-oriented approach for response was capable of accurately predicting a response to hormone therapy in patients with advanced stage disease. 46 Hormonal chemotherapy can be effective, if it is carried out selectively on such patients with low-AR expression.
Seesaw theory
Relapses after new hormonal therapy are treated with docetaxel or cabazitaxel, but for relapses after that, physicians would often carry out BSC. However, new hormonal therapy rechallenge after chemotherapy can sometimes reduce PSA again and improve the situation. Onishi et al. explained that ethinylestradiol rechallenge for CRPC led to a prolonged disease control in selected patients. 47 Abiraterone acetate rechallenge also decreased PSA in heavily pre-treated CRPC patients. 48 We also observed the patients whose PSA was decreased by enzalutamide after heavily pre-treatments including chemotherapy (Fig. 2) . Although rechallenge is not applicable to all CRPC patients, hormonal therapy can be attempted before starting BSC. A similar phenomenon was observed in a patient who had metastatic anaplastic lymphoma kinase-rearranged lung cancer -resistance to crizotinib developed because of a mutation in the anaplastic lymphoma kinase domain. 49 They showed that clonal progression was related with resensitization to crizotinib against lorlatinib anaplastic lymphoma kinase resistance mutation L1198F. 49 The present authors formulated the following hypothesis as to why rechallenge is effective for CRPC after some hormonal therapies and chemotherapy (Fig. 3) . CRPC is in a situation where two clonal cell populations, HHSPC and AIPC, are mixed. New hormonal therapy, of course, is only effective for HHSPC cells. Docetaxel might inhibit the proliferation of HHSPC to some degree. In contrast, the COU-AA-301 trial and AFFIRM trial showed that HHSPC can survive after docetaxel treatment, because abiraterone and enzalutamide were still effective after docetaxel. 50, 51 In other words, the effect of docetaxel is restrictive for HHSPC. In contrast, new hormonal therapy decreases the number of HHSPC cells, but might be ineffective for AIPC. When chemotherapy is then carried out, the number of AIPC cells decreases, but surviving HHSPC and stem cell-derived HSPC might increase again. 52, 53 If new hormonal therapy is carried out thereafter again, HHSPC cells decrease and AIPC cells increase again. Eventually, AIPC cells become resistant to all treatments, and kill the patient. Alternating hormonal therapy and chemotherapy in this way causes changes in the ratio of HHSPC and AIPC cells, an effect that seems like a seesaw (seesaw theory). In addition, it is thought that prostatic cancer progresses further through interactions between HSPC and AIPC (our unpublished data). The abovementioned CHAARTED and STAMPEDE trials might be effective, presumably because HSPC and AIPC are simultaneously attacked by hormone chemotherapy and thus this seesaw does not move.
Border attack by Ra-223
Japanese health insurance started to cover the treatment of Ra-223 for CRPC with bone metastasis in 2016. According to the ALSYMPCA trial using Ra-223, Ra-223, as compared with placebo, significantly improved overall survival (median 14.0 months vs 11.2 months). 54 Furthermore, the time to the first symptomatic skeletal event was longer with Ra-223 than with a placebo (median 15.6 months vs 9.8 months). 55 However, in a phase II study using Ra-223, a lot of cases where PSA was elevated were observed, although Alp was decreased. 56 Even in a phase II study in Japan using Ra-223, the mean change rate of PSA by Ra-223 was rather increased to 97.3% and 230.5%, although the mean change rate of Alp was À19.3% and À1.9% at 12 weeks after the first treatment and 4 weeks after the final treatment, respectively. We experienced the case that PSA continued being elevated, although bone-derived Alp and BSI on bone scintigraphy were improved by Ra-223. 57, 58 It remains unclear why such a discrepancy occurs by Ra-223. A feature is that a flying distance of alpha particle which Ra-223 releases is extremely short short. 59 This is the reason why the incidence of myelosuppression caused by Ra-223 is low compared with Sr-89. A short flying distance of alpha particle is a problem. Previously, we studied the repression of osteoplastic bone metastases of prostate cancer by bisphosphonate in vivo. 60 We noticed that many prostate caner cells still remained in the bone marrow although bisphosphonate existing in the bone matrix could prevent cancer cells from infiltrating into a bone matrix at that time ( Fig. 2 in Miwa et al. 60 ). From this observation, we hypothesized that Ra-223, as well as bisphosphonate, cannot destroy cancer cells existing in the remote area from a bone matrix distantly, although alpha particles from Ra-223 kill cancer cells near the bone matrix. However, as prostate cancer cells living in the remote area from the bone matrix continue secreting PSA, PSA can be elevated. This speculation might explain the discrepancy between PSA and BSI/Alp (border attack by Ra-223). Post-hoc analysis of the ALSYMPCA trial showed that median overall survival was also longer in patients who received Ra-223 plus abiraterone, enzalutamide or both than in those who did not receive these agents. 61 Furthermore, according to the result of the ALSYMPCA trial, it is considered that it was the most effective to use Ra-223 for patients with moderate bone metastases (extent of disease score: 2-3 or 2-7% of BSI). When physicians use Ra-223 for bone metastasis, it is necessary to evaluate the degree of bone metastasis precisely, and consider concomitant drugs.
Evaluation of image
A decline and an elevation of the serum PSA value are the effective biomarkers when physicians judge the regression and the recurrence of prostate cancer. However, they sometimes experience that patients' symptoms worsen, and the results of imaging are poor even if an absolute value of the PSA is low. Furthermore, the PSA value might not become the prognostic marker. 62, 63 As advanced prostate cancer often metastasizes to bone, it is extremely important to evaluate the change of bone metastasis. The extent of disease on bone scintigraphy was used to stratify the level of bone metastasis. 64 However, it was difficult to quantitatively monitor the extent of disease. Therefore, the Prostate Cancer Clinical Trials Working Group 3 recommends using bone scintigraphy only for progression of bone metastasis. 65 Recently, a computer-aided diagnosis system on bone scintigraphy was developed for improving the interpretations of bone scan images. The computer-aided diagnosis system shows the BSI, which provides a quantitative measure of the percentage of the adult skeleton involved in bone metastases. 57, 66 BSI on bone scintigraphy was a predictor of overall survival. [67] [68] [69] Measurement of BSI showed that PSA is not always correlated with the level of bone metastasis. 29 The Prostate Cancer Clinical Trials Working Group 3 also recommends computed tomography to evaluate lymph node metastases and visceral metastases. 65 It is extremely important to evaluate not only the PSA value, but also various images regularly, and to treat CRPC.
Conclusion
When physicians choose the therapy for patients with CRPC, it is extremely important to judge comprehensively in consideration of the following: (i) the effectiveness of therapeutic drugs based on evidence in Japan; (ii) the PSA nadir level and the situation of the progress after CRPC; (ii) treatment responsiveness for vintage and new hormonal therapy; (iv) the evaluation of the image; and (v) the adverse events of the treatment.
